Lonza will provide process development and cGMP manufacturing for Genmab’s monoclonal antibody HuMax-TF in its Slough, UK facility. The antibody, which is expressed using Lonza’s GS Gene Expression System, will be conjugated at Lonza's plant in Visp, CH to a cytotoxic drug to form the antibody drug conjugate.
GEN
Monday 31 October 2011
Lonza to manufacture GenMab's HuMax-TF
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment